~~<i id='E8860A7DC0'><strike id='E8860A7DC0'><tt id='E8860A7DC0'><pre id='E8860A7DC0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：comprehensive 2025-10-01 01:00:20 - browse：592

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Report: NIH

focus

hotspot

leisure time

focus

hotspot

DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm

WSS

The EPA's new lead rule: How one expert crunched the numbers

Rep. Raul Ruiz on the physician shortage and more

David Sabatini, ex

Heat waves linked to early deliveries, preterm births in new study

What to do when lifesaving products contribute to climate change

U.K. Biobank has 500,000 peoples' genome sequences available

knowledge

hotspot

focus

At least 13 dead in Texas as scorching temps continue

Addiction doctors spar with methadone clinics over legislation

Affirmative action in medical school literally saved lives

As biotech industry slumps, bioscience job market is upside down

Hollywood unions extend contract negotiations for actors

As biotech industry slumps, bioscience job market is upside down

The high cost of giving birth even with insurance

What don’t we know about an Alzheimer’s drug side effect?

23andMe had bad news about my health. I wish a person had delivered it

Dark money group runs ads on China biotech bill

hotspot

How to pay for weight loss drugs and save Medicare

Do more moles mean more problems? Not so, says new study

iTeos Therapeutics debuts first data on TIGIT

Dark money group runs ads on China biotech bill

Dark money group runs ads on China biotech bill

Health insurers say they are turning to AI to cut costs, improve care

leisure time

focus

focus

hotspot